U.S. Energy Services Stock News

Uber Technologies (UBER) has been on a choppy ride lately, with the stock slipping around 3 % over the past month and roughly 17 % in the past 3 months despite solid long term returns. See our latest analysis for Uber Technologies. The recent pullback comes after a strong run, with the share price still up solidly year to date and backed by a robust 1 year and 3 year total shareholder return. This suggests long term momentum rather than a structural breakdown in the story. If Uber’s moves...

Taysha Gene Therapies (TSHA) has caught investors attention after securing FDA Breakthrough Therapy Designation for its Rett syndrome candidate TSHA-102 and locking in a pivotal REVEAL trial design with an interim analysis aimed at a future filing. See our latest analysis for Taysha Gene Therapies. The excitement around TSHA-102 and the FDA Breakthrough Therapy Designation has helped fuel a powerful rerating, with the stock posting a 30 day share price return of about 29 percent and a roughly...

In recent months, analysts have highlighted Delek Logistics Partners LP’s resilience amid oil price volatility, citing stronger operating margins, revenue growth, and rising third‑party client activity, alongside healthy liquidity and high distribution yields. An interesting angle is that this operational improvement and growing third‑party business suggest Delek Logistics Partners is becoming less dependent on its sponsor, potentially broadening and stabilizing its cash flow base over...

Talen Energy (TLN) just turned heads in the latest PJM capacity auction, clearing 8,745 megawatts at rich prices, and now the stock is riding a wave of AI driven power demand optimism. See our latest analysis for Talen Energy. Those PJM wins and the leadership reshuffle seem to be reinforcing a story investors already liked. The latest share price is $380.75, and a strong year-to-date share price return of 79.40 percent has pushed the 1-year total shareholder return to 84.07 percent,...

Crinetics Pharmaceuticals (CRNX) has been quietly grinding higher, with the stock up around 11% over the past month and more than 36% in the past 3 months, drawing fresh attention from biotech investors. See our latest analysis for Crinetics Pharmaceuticals. That recent 11.5% 1 month share price return caps a sharp 36.2% 3 month share price rebound for Crinetics, even though the year to date share price return remains slightly negative and the 1 year total shareholder return is still in the...

Booking Holdings (BKNG) is back in the spotlight after raising its transformation program savings target to as much as $550 million, unveiling a viagogo partnership, and facing fresh legal risk from a Berlin court ruling. See our latest analysis for Booking Holdings. Those cost savings, new partnerships, and the Berlin ruling all land as the share price trades around $5,439, with a robust 1 month share price return of 11.57 percent and a powerful 3 year total shareholder return of 182.22...

Advanced Micro Devices (AMD) just landed in the spotlight after reports that Alibaba may order 40,000 to 50,000 MI308 AI accelerators, a move enabled by renewed U.S. approval for limited GPU exports to China. See our latest analysis for Advanced Micro Devices. The Alibaba headlines land on top of a powerful run, with AMD’s 90 day share price return of about 33% and one year total shareholder return above 70%. This shows that momentum is still very much building around its AI story. If this...

Boeing (BA) just picked up a multi year U.S. Navy contract to upgrade and extend the life of F/A 18E/F Super Hornets, giving investors clearer defense revenue visibility through 2028 despite softer commercial orders. See our latest analysis for Boeing. The contract news lands after a busy few months, from Moody’s reaffirming Boeing’s credit rating to Citi calling it a turnaround play and investors cheering commentary that the stock has likely bottomed. The backdrop is a 20.67% 1 month share...

Merck (MRK) has outpaced the broader market recently, with shares up roughly 7% over the past month and more than 30% in the past 3 months. This performance has put its valuation firmly back in focus. See our latest analysis for Merck. Zooming out, Merck’s recent 90 day share price return of 31.84% and 1 year total shareholder return of 9.59% suggest momentum is clearly building rather than fading at its current share price of $105.04. If Merck’s run has you rethinking the healthcare space,...

Wondering if Broadcom is still worth buying after its massive run, or if you are turning up late to the party? This breakdown will help you figure out whether the current price stacks up against its fundamentals. Over the last week the stock is up 7.1%, even after a 7.6% slide over the past month, and it is still boasting a hefty 50.6% gain year to date and 47.1% over the last year, on top of eye catching 3 and 5 year returns of 570.5% and 793.0% respectively. Recent headlines have focused...

Wondering if McKesson is still worth buying after such a big run, or if the value has already been priced in? This breakdown is designed to help you decide with confidence. After climbing 45.8% year to date and 43.2% over the last year, the stock has cooled slightly, with a 1.9% gain in the past week and a 4.7% pullback over the last month. This hints at both strong momentum and rising questions about upside from here. Recent headlines have focused on McKesson expanding its role in...

Wix.com (WIX) just doubled down on its global commerce ambitions, rolling out more local payment options across Europe and plugging Stripe’s new Agentic Commerce Suite into its platform to better tap emerging AI-driven sales channels. See our latest analysis for Wix.com. Even with these product wins and a $104.71 latest share price, momentum has been mixed, with a strong 1 month share price return but a sharply negative year to date share price return and a still solid 3 year total...

Wondering if Novavax at around $6.80 is a bargain or a value trap? You are not alone, and that is exactly what we are going to unpack here. The stock has nudged up about 4.1% over the last week and 2.6% over the last month, but those short term gains still sit against a much tougher backdrop, with the share price down around 20.7% year to date and 94.3% over five years. Recent moves have been shaped by shifting market sentiment around the long term demand for Novavax's COVID related products...

If you have been wondering whether Fortinet is a bargain or a value trap at today’s price, you are not alone. This breakdown is designed to give you a clear, no jargon answer. Despite being down about 14.9% year to date and 17.5% over the last year, the stock has still delivered a 68.5% return over 3 years and 172.5% over 5 years, which indicates that longer term holders have been rewarded for their patience. Recent moves in Fortinet’s share price have been shaped by ongoing demand for...

Wondering whether Rezolve AI at around $2.80 is a bargain in the making or a value trap, this article will walk you through the numbers in plain English. The stock has bounced 16.7% over the last week even though it is still down 12.5% over 30 days and 31.5% year to date, and long term holders are sitting on a 72.3% drawdown over three years. That recent short term strength has come as investors refocus on Rezolve AI's position in AI driven software, with renewed interest in smaller names...

In December 2025, Oklo announced it had completed multi-day uranium fast reactor critical tests with Los Alamos National Laboratory at the U.S. Department of Energy's National Criticality Experiments Research Center, marking the first public technical milestone for its Pluto fast test reactor project. This early validation work on surplus uranium as a potential bridge fuel is a key step toward Oklo’s longer-term plan to power its compact Aurora reactors for data centers and grid...

Rocket Lab (RKLB) just landed its largest ever U.S. Space Development Agency contract to build 18 missile warning satellites, while also setting a record year for flawless Electron launches. The stock has surged accordingly. See our latest analysis for Rocket Lab. That backdrop of record government wins and flawless launches has clearly shifted how investors see Rocket Lab, with an 81.8% 1 month share price return and a 2055.87% 3 year total shareholder return pointing to strong, still...

In recent months, Qualivian Investment Partners exited its position in Copart, Inc. after citing increased competition and a softer fundamental backdrop, including slower volumes from the insurance vertical that contributes about 80% of Copart’s revenues. The firm specifically pointed to RB Global-backed IAA’s more aggressive pricing and the loss of a national insurance carrier contract, underscoring how shifts in insurer relationships can quickly alter the economics of Copart’s core...

Nucor recently cut its fourth-quarter 2025 earnings guidance, citing seasonal factors and fewer shipping days, while also announcing that Stephen D. Laxton will become President and COO as David A. Sumoski prepares to retire in June 2026. These moves coincided with insider selling by CEO Leon J. Topalian and Executive Vice President Allen Behr, developments that may influence how investors interpret Nucor’s leadership stability and earnings outlook. We’ll now examine how the earnings...

If you are wondering whether CACI International is still worth considering after a big run, or if most of the upside is already priced in, this breakdown is designed to help you figure that out without getting lost in jargon. The stock has cooled off recently, slipping about 2.8% over the last week and 9.2% over the past month. It is still up 32.5% year to date and 34.5% over the last year, with returns of 79.8% over 3 years and 118.7% over 5 years. Behind those moves, investors have been...

Axalta Coating Systems (AXTA) has quietly put together a steady run, with the stock up around 7% over the past month and roughly 10% in the past 3 months, despite a weaker year-to-date showing. See our latest analysis for Axalta Coating Systems. With the share price now around $32.24, the recent 30 day share price return of nearly 7 percent contrasts with a slightly negative year to date move. At the same time, multi year total shareholder returns suggest momentum is gradually rebuilding...

EyePoint (EYPT) has been drawing attention after fresh upward revisions to its earnings estimates and strong momentum scores, a combination that often signals shifting expectations for a company’s financial trajectory. See our latest analysis for EyePoint. The latest leg higher, including a 1 day share price return of 8.15 percent and 30 day share price return of 37.79 percent, adds to a powerful year to date share price return of 134.74 percent and a 3 year total shareholder return of 552.25...

Earlier in December, Kiniksa Pharmaceuticals International received a Buy rating from a Wells Fargo analyst and released an update on its Phase 2 study of KPL-387 monotherapy in recurrent pericarditis, which aims to transition patients from existing regimens to this new therapy. This combination of a positive analyst view and progress on KPL-387, a key pipeline asset, sharpened investor focus on Kiniksa’s long-term portfolio beyond ARCALYST. We’ll now examine how the latest KPL-387 clinical...

Alvotech and Teva Pharmaceuticals previously reached a settlement and license agreement with Regeneron, clearing a legal path for AVT06, Alvotech’s proposed biosimilar to Eylea, to enter the US market by late 2026, following earlier marketing approvals in the UK, Japan and across the European Economic Area and positive phase 3 data in wet AMD. This resolution removes a key layer of legal uncertainty around AVT06’s US commercialization, potentially reinforcing Alvotech’s broader biosimilar...